Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;145(1):245-54.
doi: 10.1007/s10549-014-2910-1. Epub 2014 Apr 6.

Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy

Affiliations

Genetic heterogeneity beyond CYP2C8*3 does not explain differential sensitivity to paclitaxel-induced neuropathy

Daniel L Hertz et al. Breast Cancer Res Treat. 2014 May.

Abstract

The development of paclitaxel-induced peripheral neuropathy (PIPN) is influenced by drug exposure and patient genetics. The purpose of this analysis was to expand on a previous reported association of CYP2C8*3 and PIPN risk by investigating additional polymorphisms in CYP2C8 and in hundreds of other genes potentially relevant to paclitaxel pharmacokinetics. Clinical data was collected prospectively in an observational registry of newly diagnosed breast cancer patients. Patients treated with paclitaxel-containing regimens were genotyped using the Affymetrix DMET™ Plus chip. Patients who carried the CYP2C8*2, *3, or *4 variant were collapsed into a low-metabolizer CYP2C8 phenotype for association with PIPN. Separately, all SNPs that surpassed quality control were assessed individually and as a composite of genetic ancestry for associations with PIPN. 412 paclitaxel-treated patients and 564 genetic markers were included in the analysis. The risk of PIPN was significantly greater in the CYP2C8 low-metabolizer group (HR = 1.722, p = 0.018); however, the influences of the *2 and *4 SNPs were not independently significant (*2: p = 0.847, *4: p = 0.408). One intronic SNP in ABCG1 (rs492338) surpassed the exploratory significance threshold for an association with PIPN in the Caucasian cohort (p = 0.0008) but not in the non-Caucasian replication group (p = 0.54). Substantial genetic variability was observed within self-reported racial groups but this genetic variability was not associated with risk of grade 2+ PIPN. The pharmacogenetic heterogeneity within a cohort of breast cancer patients is dramatic, though we did not find evidence that this heterogeneity directly influences the risk of PIPN beyond the contribution of CYP2C8*3.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest:

L. Scott Clark is an employee of Gentris Corp. Howard L. McLeod and Alison A. Motsinger-Reif were consultants for Gentris Corp.

Figures

Fig 1
Fig 1
Incidence of grade 2+ neuropathy by CYP2C8 metabolizer status. All patients carrying a CYP2C8*2, *3 or *4 allele were grouped into a low-metabolizer phenotype. As hypothesized, CYP2C8 low-metabolizers had a greater risk of neuropathy (p=0.02).
Fig 2
Fig 2
Incidence of grade 2+ neuropathy by ABCG1 (rs492338) genotype in Caucasian (n=285) (Fig 2A, left) and non-Caucasian (n=124) (Fig 2B, right) patients. The increase in neuropathy risk for patients carrying rs492338 discovered in Caucasians (p=0.0008) could not be replicated in non-Caucasians (p=0.542), suggesting that if the original association is true it may be race-specific.
Fig 3
Fig 3
Stacked bar plots displaying the percentage of Caucasian (green), African (blue), and Asian (red) ancestry, visualized in ascending order of Caucasian genetics stratified by self-reported race. Race was verified by other documentation within the medical record for all patients whose genetic ancestry was <80% concordant with their self-reported race. The self-reported white patients are genetically predominantly Caucasian; however, some patients have substantial African and/or Asian genetic ancestry. Similarly, the self-reported black patients exist on a continuum between almost entirely genetically African and almost entirely genetically Caucasian. Interestingly, Asians are the most genetically homogeneous of the racial groups.
Fig 4
Fig 4
Plot of first two principal components for 412 breast cancer patients and 359 reference samples (YRI=118, JPT=91, CHB=90, CEU=59). The reference samples tightly cluster by race due to genetic homogeneity. The patient samples tend to cluster near the corresponding reference samples but demonstrate substantially greater genetic heterogeneity, particularly for the self-reported black patients who represent a continuum between the African and Caucasian reference populations.

References

    1. Diéras V, Fumoleau P, Romieu G, Tubiana-Hulin M, Namer M, Mauriac L, et al. Randomized parallel study of doxorubicin plus paclitaxel and doxorubicin plus cyclophosphamide as neoadjuvant treatment of patients with breast cancer. J Clin Oncol. 2004 Dec 15;22(24):4958–65. - PubMed
    1. Martin M, Rodriguez-Lescure Ã, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, et al. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer. J Natl Cancer Inst. 2008 Jun 04;100(11):805–14. - PubMed
    1. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003 Mar 15;21(6):976–83. - PubMed
    1. Freilich RJ, Balmaceda C, Seidman AD, Rubin M, DeAngelis LM. Motor neuropathy due to docetaxel and paclitaxel. Neurology. 1996 Jul 01;47(1):115–8. - PubMed
    1. Mielke S, Mross K, Gerds TA, Schmidt A, Wasch R, Berger DP, et al. Comparative neurotoxicity of weekly non-break paclitaxel infusions over 1 versus 3 h. Anticancer Drugs. 2003;14(10):785–92. - PubMed

Publication types

MeSH terms

LinkOut - more resources